This site is intended for Healthcare professionals only.
×

Dr Reddy’s launches Sevelamer Carbonate in the US market


Dr Reddy’s launches Sevelamer Carbonate in the US market

The newly launched Sevelamer Carbonate is in the strengths of 0.8 g and 2.4 g packets and is a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for oral suspension, approved by the US Food and Drug Administration (USFDA), Dr Reddy’s Laboratories said in a BSE filing.

New Delhi: Drug major Dr Reddy’s Laboratories on Thursday announced the launch of Sevelamer Carbonate for oral suspension, used for controlling serum phosphorus in patients with chronic kidney disease on dialysis, in the US market.

The newly launched product is in the strengths of 0.8 g and 2.4 g packets and is a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for oral suspension, approved by the US Food and Drug Administration (USFDA), Dr Reddy’s Laboratories said in a BSE filing.

Quoting IMS Health data, the company said the Renvela brand and generic had US sales of approximately USD 101 million for the most recent 12 months ending in October 2018.

The following two tabs change content below.
Farhat Nasim

Farhat Nasim

Farhat Nasim joined Medical Dialogue as Reporter in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier's College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751


Source: PTI
0 comment(s) on Dr Reddy’s launches Sevelamer Carbonate in the US market

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted